Compare Hims and Hers Health Inc (HIMS) vs Nike Inc (NKE) Price & Performance

Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.

The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.

Nike's stock trades at $34.36, down 0.72% with a bearish technical outlook. The company reported $46.31B in revenue for 2025 with a 6.74% net margin, though earnings have beaten expectations in recent quarters. Analyst consensus remains positive with a $36.98 price target, while recent news highlights challenges in China and inventory management.

Nike faces near-term headwinds from slowing revenue growth and margin pressure, but strong brand positioning and consistent earnings beats provide upside potential. Key risks include consumer demand weakness and competitive pressures, while institutional sentiment remains cautiously optimistic for a turnaround.